skip to content

Trading statements

Dechra revenues rise

17 January 2017 07:58

Dechra Pharmaceuticals says reported group revenue for the six months to the end of December increased by approximately 34% at constant exchange rate (56% at actual exchange rate).

Core group revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.

Dechra says all acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of the board's expectations.

Chief executive Ian Page said: "Our underlying business and acquisitions have performed well, resulting in significant growth in the first half of the 2017 financial year. The Group pipeline has delivered new products and our global presence continues to increase. We remain confident in our strategy, our future prospects and our expectations for full year performance."

Story provided by

Related Company: DPH

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.